Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin and Radiation in Locally Advanced Pancreatic Cancer
NCT00026403Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 2001
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in pancreatic adenocarcinoma (PDAC), sponsored by Cancer and Leukemia Group B. Primary endpoint: 1-year survival. Started Sep 2001; status: completed.
02
Drugs
gemcitabinecisplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00026403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00026403.